PTC Therapeutics Profit Margin

The latest profit margin for PTCT is -3.8% as of June 2026. That compares with 36.93% in the prior-year period — down 110.3% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside PTC Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTCT's profit margin moved from 36.93% to -3.8% — a 110.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PTC Therapeutics's valuation or profitability profile.

Against Healthcare companies, PTCT currently prints -3.8% for profit margin, while the sector average sits near 21.34%. That is roughly 117.8% below the sector mean. Large gaps often invite a closer look at PTC Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively PTC Therapeutics converts resources into returns. At -3.8%, PTCT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 36.93% in the prior-year period — down 110.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PTCT's profit margin (-3.8%), review year-over-year change from 36.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.